Inflammatory Disease Market Size to Surge to USD 241.34 Billion by 2035

According to Precedence Research, the global inflammatory disease market size was valued at USD 125.00 billion in 2025 and is projected to surge to USD 241.34 billion by 2035, expanding at a CAGR of 6.80% from 2026 to 2035. This surge is driven by an increasing prevalence of chronic inflammatory disorders, growing demand for targeted therapies, and advancements in biologics and diagnostics. As the market continues to evolve, innovative treatments and digital health solutions are revolutionizing the approach to managing immune-mediated inflammatory diseases.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉 https://www.precedenceresearch.com/sample/8327

Inflammatory Disease Market Size and Forecasts

• Market size in 2025: USD 125.00 Billion
• Market size in 2026: USD 133.50 Billion
• Market size by 2035: USD 241.34 Billion
• CAGR: 6.80% (2026-2035)
• Forecast period: 2026-2035
• Base year: 2025

The Role of AI in Revolutionizing Inflammatory Disease Treatment

Artificial Intelligence (AI) is playing a pivotal role in transforming how inflammatory diseases are diagnosed and treated. AI-driven tools help in identifying disease patterns and predicting treatment outcomes by analyzing vast amounts of clinical data, radiographic images, and biomarkers. In personalized medicine, AI leverages patient-specific data from genomics, proteomics, and clinical history to recommend customized therapies, improving treatment outcomes and patient care.

AI's Contribution in Disease Identification: AI-powered diagnostic tools are helping to detect inflammatory diseases at an earlier stage. For example, the identification of rheumatoid arthritis, inflammatory bowel disease, and psoriasis has become more accurate, enabling faster intervention and better management of these chronic conditions.

Personalized Treatment and Clinical Outcomes: In addition to diagnosing diseases earlier, AI also plays a critical role in personalizing treatments. By incorporating genetic information, AI enables the formulation of highly tailored treatment strategies, ensuring higher efficacy and reducing adverse effects for patients. This approach is expected to continue expanding as AI technologies evolve and improve.

🔗 What's Fueling the Next Wave of Growth? 👉 https://www.precedenceresearch.com/inflammatory-disease-market

Inflammatory Disease Market Growth Factors

🔸 Rising Prevalence of Chronic Inflammatory Diseases: The increasing incidence of conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, and asthma is directly linked to the market's expansion. A rise in lifestyle diseases, urbanization, and environmental changes have contributed to the growing number of patients suffering from chronic inflammation.

🔸 Advancements in Diagnostic and Treatment Options: With improvements in diagnostic tools, early detection of these diseases has become more accessible, allowing for better management and intervention. Moreover, novel therapies such as biologics and biosimilars are offering more targeted and effective treatment options.

🔸 Expanding Healthcare Infrastructure and Awareness: Greater awareness about inflammatory diseases and the increase in healthcare facilities worldwide are improving early diagnosis and patient access to treatments. Furthermore, government and non-governmental initiatives focused on chronic disease management are helping propel market growth.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Inflammatory Disease Market Opportunities & Trends

🔹 Focus on Targeted Therapies and Personalized Medicine: There is a surge in demand for biologics and targeted therapies that can efficiently manage chronic inflammatory diseases. These treatments promise fewer side effects, making them an attractive option for patients and healthcare providers alike.

🔹 Advancements in Biosimilars: The increasing affordability of biosimilars due to their lower cost compared to branded biologics presents a significant opportunity in the market, especially in emerging markets where cost barriers are a major concern.

🔹 Patient-Centric Care: The shift towards patient-centric models, involving shared decision-making and personalized treatment plans, is set to dominate the market. Digital health technologies such as mobile health apps and wearable devices are playing a critical role in improving patient adherence and monitoring disease progress remotely.

🔹 FPR2 Agonist Therapies: A new class of drugs designed to enhance natural inflammation resolution pathways is gaining attention. These therapies are positioned to treat diseases by "healing" the immune system rather than merely suppressing it, paving the way for more long-term solutions.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉 https://www.precedenceresearch.com/checkout/8327

Inflammatory Disease Market Regional Outlook

North America dominated the market with a 40% share in 2025, supported by advanced healthcare systems, high biologics adoption, and strong R&D activity. The United States accounted for the largest regional share, driven by advanced therapeutics, high disease awareness, and presence of leading pharmaceutical companies.

Asia Pacific held 25% share and is expected to grow fastest at 8.2% CAGR. Rising disease prevalence, improving healthcare infrastructure, and increasing awareness are key drivers. China is emerging as a high-growth market due to large patient population, healthcare investments, and expanding insurance coverage.

Europe accounted for 25% share with steady growth at 6.2% CAGR. Strong healthcare systems and increased adoption of biologics and biosimilars support growth. The United Kingdom plays a key role in Europe, with strong clinical research activity and broad access to advanced therapies through public healthcare systems.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@ https://www.precedenceresearch.com/sample/8327

Inflammatory Disease Market Segmental Outlook

🔹 Disease Type Insights

The Rheumatoid Arthritis segment led the inflammatory disease market with a 30% share in 2025. Growth is driven by increasing adoption of biologics and targeted therapies for long-term disease management. Improved early diagnosis and better healthcare access, along with innovations like TNF, IL-6, and JAK inhibitors, are significantly enhancing patient outcomes.

Inflammatory Bowel Disease (IBD) accounted for 20% of the market in 2025 and is expected to grow at the fastest CAGR of 7.8%. Rising cases of Crohn's disease and ulcerative colitis, along with advancements in imaging and biomarker-based diagnostics, are improving disease detection and management.

The Psoriasis & Psoriatic Arthritis segment held a 20% share in 2025, growing at a CAGR of 6.5%. Increased awareness and the use of IL-17 and IL-23 inhibitors have improved treatment outcomes and patient quality of life.

Asthma and other chronic respiratory inflammatory diseases represented 20% of the market in 2025, with a projected CAGR of 7.2%. Growth is fueled by pollution, urbanization, and rising allergen exposure, while therapies like inhaled corticosteroids and biologics are improving care.

🔹 Drug Class Insights

Biologics dominated with a 45% share in 2025 due to their ability to target specific inflammatory pathways. TNF inhibitors, interleukin inhibitors, and JAK inhibitors have transformed chronic disease management with high efficacy and fewer side effects.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) held a 15% share and are expected to grow at a CAGR of 4.5%. Their affordability and accessibility make them a common first-line treatment for mild to moderate inflammation.

Corticosteroids accounted for 15% of the market, valued for rapid symptom relief. Immunosuppressants also held 15%, playing a critical role in treating severe autoimmune conditions by controlling immune system activity.

Biosimilars captured 10% of the market and are expected to grow fastest at 9.5% CAGR. Their lower cost and increasing patent expirations of biologics are making advanced treatments more accessible.

🔹 Route of Administration Insights

Injectable therapies led with a 55% market share in 2025, driven by widespread use of biologics administered intravenously or subcutaneously. They are preferred for moderate to severe conditions due to higher effectiveness and faster action.

Oral treatments held 35% share and are projected to grow at 6% CAGR. Their convenience, affordability, and suitability for long-term management make them highly preferred by patients.

Topical therapies accounted for 10% of the market, growing at 5.5% CAGR. They are widely used for localized conditions like skin inflammation, offering targeted treatment with fewer systemic side effects.

🔹 Distribution Channel Insights

Hospital pharmacies dominated with a 45% share in 2025 due to high patient inflow and administration of complex therapies like biologics in clinical settings.

Retail pharmacies held 35% share and are growing at 6.2% CAGR. Convenience, accessibility, and expanding pharmacy networks are key growth drivers.

Online pharmacies captured 20% share and are expected to grow fastest at 9% CAGR. Increased digital adoption, home delivery, and discounted pricing are boosting demand.

🔹 End-Use Insights

Hospitals led the market with a 50% share in 2025 due to their role in managing severe and complex inflammatory diseases with advanced infrastructure and specialized care.

Specialty clinics held 30% share and are projected to grow fastest at 7.5% CAGR. Their focused expertise enables better diagnosis and personalized treatment.

Homecare accounted for 20% share and is growing at 7% CAGR. Increased use of remote monitoring and drug delivery devices is enabling convenient long-term treatment at home.

Top Companies in the Inflammatory Disease Market and Their Offerings

➢ AbbVie Inc.
↳ Humira (adalimumab) - TNF‐alpha inhibitor for rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, etc. (historically blockbuster).
↳ Skyrizi (risankizumab) - IL‐23 inhibitor for plaque psoriasis, psoriatic arthritis, and IBD.
↳ Rinvoq (upadacitinib) - Oral JAK inhibitor for RA, atopic dermatitis, psoriatic arthritis, and IBD indications.
↳ Broad inflammation/immunology pipeline with additional indications expanding these core agents.

➢ Johnson & Johnson
↳ Portfolio includes advanced immunology and inflammatory disease therapies across autoantibody diseases, gastroenterology (IBD), dermatology, and rheumatology.
↳ Key marketed immunology agents include products like Tremfya (guselkumab) for psoriasis and psoriatic arthritis, Stelara (ustekinumab) for Crohn's disease and psoriasis, and others (J&J's pharma division/Janssen immunology).
(Note: J&J's broad immunology pipeline targets many IMIDs).

➢ Pfizer Inc.
↳ Active in Inflammation & Immunology with marketed therapies and an ongoing clinical pipeline targeting chronic inflammatory and autoimmune conditions.
↳ Offers biologics and small molecules for immune‐mediated disorders; biosimilar infliximab products (e.g., Inflectra) reference anti‐TNF activity.
↳ Pipeline includes novel immunology/inflammation candidates.

➢ Novartis AG
↳ Developing oral anti‐inflammatory therapies via collaboration with Matchpoint Therapeutics.
↳ Portfolio historically includes IL‐17/IL‐23 targeted agents (e.g., Cosentyx for psoriasis), and involvement in inflammatory indications.

➢ Amgen Inc.
↳ Offers Enbrel (etanercept) - a TNF inhibitor for RA, PsA, ankylosing spondylitis, and plaque psoriasis (often via biosimilars).
↳ Involved in inflammation area with Tezspire (tezepelumab) (in collaboration with AstraZeneca) for chronic inflammatory conditions (expanded sinus disease approval).

➢ Roche Holding AG
↳ Actemra (tocilizumab) - IL‐6 receptor antagonist for RA and systemic inflammation.
↳ Investigational TL1A‐targeting antibodies (e.g., afimkibart) for IBD and atopic dermatitis.

➢ Sanofi S.A.
↳ Dupixent (dupilumab) - IL‐4/IL‐13 antagonist for multiple type 2 inflammatory diseases (atopic dermatitis, asthma, etc.).
↳ Expanding portfolio with bispecific antibodies targeting IBD and broader autoimmune pathways.

➢ Bristol Myers Squibb
↳ Immunology and inflammation presence includes Orencia (abatacept) for RA, along with broader immuno‐modulators.
↳ Pipeline aligned to inflammatory biology as part of broader immunology strategy.

➢ Eli Lilly and Company
↳ Taltz (ixekizumab) - IL‐17A antagonist for psoriasis and PsA, used in inflammatory disease settings.
↳ Small‐molecule and biologic programs in targeted inflammation pathways.

➢ Merck & Co., Inc.
↳ Presence in broader inflammatory disease market through targeted therapies and immunomodulators (e.g., with anti‐inflammatory indications embedded in larger immunology portfolio).

➢ GlaxoSmithKline plc (GSK)
↳ Nucala (mepolizumab) - IL‐5 antagonist for eosinophilic asthma and related inflammatory conditions.
↳ Focus on immunology expansion via acquisitions (e.g., CMG1A46) to bolster inflammatory pipeline.

➢ Takeda Pharmaceutical Company Limited
↳ Works across inflammatory and autoimmune disease spaces with targeted agents and biologics.
↳ Products and pipeline span GI‐related inflammation and broader IMIDs.

➢ UCB S.A.
↳ Offers therapies targeting chronic inflammatory disorders (notably in rheumatology/autoimmune diseases).

➢ Biogen Inc.
↳ While primarily focused on neurodegenerative diseases, Biogen has involvement in immune‐mediated inflammation research segments.

➢ Regeneron Pharmaceuticals, Inc.
↳ Dupixent (in partnership with Sanofi) - IL‐4/IL‐13 inhibitor widely used in type 2 inflammatory diseases.
↳ Regeneron's pipeline also includes agents targeting inflammatory pathways.

Recent Updates

⚡ OSE Immunotherapeutics recently announced the presentation of a new FPR2 agonist monoclonal antibody at the 2026 Annual Meeting of the American Association of Immunologists (AAI). This breakthrough treatment is poised to enhance the resolution of inflammation in chronic inflammatory diseases.

⚡ In November 2025, Animate Biosciences launched the AnimateIQTM platform, a generative AI tool aimed at accelerating the development of peptide therapeutics for inflammatory and fibrotic diseases.

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/8327

Segments Covered in the Report

🔸 By Disease Type

Rheumatoid Arthritis
Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
Psoriasis & Psoriatic Arthritis
Asthma & Chronic Inflammatory Respiratory Diseases
Multiple Sclerosis & Neuroinflammatory Disorders

🔸 By Drug Class

Biologics (TNF Inhibitors, IL Inhibitors, JAK Inhibitors)
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Immunosuppressants
Biosimilars

🔸 By Route of Administration

Injectable (Subcutaneous & Intravenous)
Oral
Topical

🔸 By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

🔸 By End-Use

Hospitals
Specialty Clinics
Homecare Settings

🔸 By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.